Corcept To Pay Investors $14M Over Off-Label Marketing Of Mifepristone
SAN FRANCISCO — Corcept Therapeutics Inc. will pay $14 million to settle class claims in which shareholders allege that the drug maker and certain of its senior executives engaged in an...To view the full article, register now.
Already a subscriber? Click here to view full article